

## A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

- diagnosis of adenocarcinoma of the prostate - cancer progression while on androgen deprivation therapy with metastasis to bone or other areas of the body - received 1 but no more than 2 taxane-based chemotherapy regimens - unable to do strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete inclusion and exclusion criteria

---

#### Exclusion Criteria:

- unable to swallow capsules/tablets - gastrointestinal disorder that might affect absorption - poorly controlled diabetes mellitus - history of clinically significant ventricular arrhythmias - known additional cancer that is progressing or has required active treatment within the past 3 years

### Conditions & Interventions

#### Conditions:

Cancer

#### Keywords:

Clinics and Surgery Center (CSC), mCRPC, metastatic castration-resistant prostate cancer, Prostate Cancer Metastatic

### More Information

**Description:** This trial is testing MK-5684 in men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation Hormonal Agent (NHA) and Taxane-based chemotherapy. This trial will compare MK-5684 to abiraterone acetate and enzalutamide. Abiraterone acetate and enzalutamide are standard treatments for mCRPC. The purpose of this trial is to test the safety of the trial drug, MK-5684, see how well the drug works, and see how the body handles the drug. We also want to see if participants who get MK-5684 live longer compared to those who get abiraterone acetate or enzalutamide.

**Study Contact:** Emmanuel Antonarakis - [anton401@umn.edu](mailto:anton401@umn.edu)

**Principal Investigator:** Emmanuel Antonarakis

**Phase:** PHASE3

**IRB**

**Number:** STUDY00021305

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.